Apteka Exhibition UFI Approved Event Euroexpo Exhibition Company
To main
For exhibitors
For visitors

Novo Nordisk announces Financial results for 2012


Novo Nordisk has announced that sales increased by 18% to 78.0 billion in DKK ($13,8 billion). Net profit increased by 25% to DKK 21.4 billion ($3.8 billion). For 2013, sales growth is expected to be 8–10%. «2012 has been another year with strong results», stated Lars Rebien Sørensen, Novo Nordisk president and CEO.

In 2012 the company’s new-generation insulins, Tresiba® and Ryzodeg® have been approved in Japan and Europe. Both products are waiting for an approval from US authorities.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with almost 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

In Russia, Novo Nordisk products are known for more than 50 years, and the company’s representative office has been working for about 20 years. Novo Nordisk has a share of around 45% of Russian insulin market and now is investing into the modern insulin plant in the Kaluga region.

Back to the list

Contacts Flashback Site map
119002 Moscow, Arbat str., 35, of. 423
Тel: +7 (495) 925-65-61/62
Fax: +7 (499) 248-07-34